This hearing will examine, among other things, China’s energy needs and clean energy policies, the recent developments in the U.S.-China clean energy cooperation, and the implications of such cooperation for the United States.
This hearing will address China’s recent healthcare reforms, market access for U.S. medical goods and services in China, and the safety of medical products imported from China into the United States. China is growing more affluent and urbanized, and is also facing new healthcare challenges. The Chinese government has launched ambitious reforms to expand coverage and improve care. This hearing will consider whether U.S. drug and medical device makers are able to compete in China’s market. It will also assess the U.S. Food and Drug Administration’s ongoing efforts to regulate drugs and drug ingredients imported from China into the United States.
This hearing will explore the evolving security dynamics in Asia and the effects of this changing environment on the United States. More specifically, it will address how Northeast Asia, Southeast Asia, and Oceania are responding to China’s rise and consider what implications follow for U.S. alliances and partnerships in the region.
This hearing will examine challenges to the U.S. economy from Chinese competition in manufacturing and the role of state-owned enterprises. In addition, this hearing will assess the effectiveness of U.S. trade laws and trade enforcement in addressing these challenges.
Panel I: China’s Perspectives and Policy in the Middle East.
Panel II: China’s Energy and Other Economic Interests in the Middle East.
Panel III: China’s Political and Security Challenges in the Middle East.
Disclaimer: The research papers in this section were prepared at the request of the Commission to support its deliberations. They are posted to the Commission's website in order to promote greater public understanding of the issues addressed b the Commission in its ongoing assessment of U.S.-China economic relations and their implications for U.S. security, as mandated by P.L.106-398 and P.L.108-7. Their posting to the endorsement by the Commission or any individual Commissioner of the views or conclusions expressed in them.